Inflarx logo.png
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
October 31, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx on large white.jpg
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
September 03, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
InflaRx on large white.jpg
InflaRx Announces Participation in September Investor Events
August 27, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx on large white.jpg
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
April 24, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx on large white.jpg
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET | InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...
InflaRx on large white.jpg
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
May 12, 2022 07:30 ET | InflaRx N.V.
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities...
Inflarx-Logo_klein.jpg
InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference
February 19, 2020 08:00 ET | InflaRx N.V.
JENA, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...